Search hospitals > New York > Bronx
Jacobi Medical Center
Claim this profileBronx, New York 10461
Global Leader in Human Immunodeficiency Virus Infection
Global Leader in HIV Infection
Conducts research for Sickle Cell Disease
Conducts research for Infections and Infestations
Conducts research for HIV/AIDS
169 reported clinical trials
4 medical researchers
Summary
Jacobi Medical Center is a medical facility located in Bronx, New York. This center is recognized for care of Human Immunodeficiency Virus Infection, HIV Infection, Sickle Cell Disease, Infections and Infestations, HIV/AIDS and other specialties. Jacobi Medical Center is involved with conducting 169 clinical trials across 221 conditions. There are 4 research doctors associated with this hospital, such as Kenneth Rivlin, MD, Abhishek Kumar, MD, Michael Rosenberg, MD, and Susan Gennaro, PhD.Area of expertise
1Human Immunodeficiency Virus Infection
Global Leader2HIV Infection
Global LeaderHIV infection positive
CD4+ T cell count positive
Top PIs
Kenneth Rivlin, MDJacobi Medical Center6 years of reported clinical research
Studies Sickle Cell Disease
Studies Sickle cell crisis
5 reported clinical trials
4 drugs studied
Abhishek Kumar, MDJacobi Medical Center1 year of reported clinical research
Studies Diarrhea
Studies Solid Tumors
3 reported clinical trials
2 drugs studied
Michael Rosenberg, MDJacobi Medical Center3 years of reported clinical research
Studies Human Immunodeficiency Virus Infection
Studies HIV Infection
1 reported clinical trial
2 drugs studied
Susan Gennaro, PhDJacobi Medical Center7 years of reported clinical research
Studies Postpartum Depression
Studies Malnutrition
1 reported clinical trial
1 drug studied
Clinical Trials running at Jacobi Medical Center
Sickle Cell Disease
COVID-19
Heart Attack
Type 1 Diabetes
Coronavirus
Thalassemia
Anemia
Post-Heart Attack Syndrome
Cardiovascular Risk
Diabetes Mellitus
Etavopivat
for Sickle Cell Anemia
Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking into how safe treatment with etavopivat is and how well it works over a long period of time. The study will last for up to 264 weeks, but it will end earlier if etavopivat is approved in the participant's country.
Recruiting2 awards Phase 3
Etavopivat
for Sickle Cell Disease
This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the participants will get is decided by chance. Etavopivat is a new medicine and is currently being tested in other studies in addition to this one. The study will last for about 2 years.
Recruiting1 award Phase 33 criteria
FTX-6058
for Sickle Cell Disease
This is a study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Pociredir in participants with sickle cell disease.
Recruiting1 award Phase 1
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Jacobi Medical Center?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.